Dr. Olivier Brandicourt
- a
- n
- i
Appointment to the Board
April 2022.
Experience and expertise
Olivier is an accomplished senior leader in the global pharmaceutical industry, being recognised for his strategic and operational skills built on 20 years of general management and ten years of medical/marketing functional experience. Olivier retired from Sanofi S.A. in September 2019 after being its chief executive officer since April 2015. Prior to joining Sanofi, he was the chief executive officer of Bayer HealthCare AG. From 2000 to 2013, he held a series of leadership positions at Pfizer of which president and general manager of global specialty care (2008 - 2009), global primary care (2009 - 2012) before becoming president and general manager of the emerging markets and established products business units. Olivier was part of the Pfizer executive team from 2010 to 2013.
Olivier studied medicine in Paris where he specialised in infectious diseases and tropical medicine and holds a Master’s in Biology and an Advanced Degree in Cellular and Immunological Pathophysiology. He is an Honorary Fellow of the Royal College of Physicians in London.
Current external appointments
Olivier is currently a senior adviser at Blackstone Life Sciences, and serves as a board director of Alnylam Pharmaceuticals, BeiGene Ltd, Dewpoint Therapeutics, and AvenCell (Chair). Olivier is on the board of directors of the National Committee on US-China Relations.